2. Signaling Pathways
  3. Anti-infection
  4. RSV

RSV

Respiratory syncytial virus

RSV

Related Products

PDF 0.17 MB

RSV (Respiratory syncytial virus) is a leading cause of acute respiratory infections. RSV can exploit host immunity and cause a strong inflammatory response that leads to lung damage and virus dissemination. There is a single RSV serotype with two major antigenic subgroups, A and B.

RSV is a non-segmented negative-sense single-stranded enveloped RNA virus that belongs to the family of Paramyxoviridae, genus Pneumovirus, subfamily Pneumovirinae. Its 10 genes encode 11 proteins since two overlapping open reading frames in the M2 mRNA yield two distinct matrix proteins, M2-1 and M2-2. The viral envelope contains three proteins, the G glycoprotein, the fusion (F) glycoprotein, and the small hydrophobic (SH) protein. The RSV virus comprises five other structural proteins, the large (L) protein, nucleocapsid (N), phosphoprotein (P), matrix (M), and M2-1, and two non-structural proteins (NS1 and NS2).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12983A
    Lumicitabine
    		Inhibitor 99.93%
    Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
    Lumicitabine
  • HY-11097
    TMC353121
    		Inhibitor
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
    TMC353121
  • HY-102038
    PC786
    		Inhibitor 99.11%
    PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM).
    PC786
  • HY-P99804
    Clesrovimab
    		Inhibitor 99.89%
    Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases.
    Clesrovimab
  • HY-149648
    JNJ-8003
    		Inhibitor 99.84%
    JNJ-8003 is a potent inhibitor of RSV Polymerase. JNJ-8003 inhibits nucleotide polymerization of RNA transcription and replication at the early stages.
    JNJ-8003
  • HY-12993
    RSV604
    		Inhibitor 99.92%
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM).
    RSV604
  • HY-145119AS
    Mindeudesivir hydrobromide
    		Inhibitor 99.46%
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
    Mindeudesivir hydrobromide
  • HY-122587
    AVG-233
    		Inhibitor 98.87%
    AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV).
    AVG-233
  • HY-147346
    Zelicapavir
    		Inhibitor 99.10%
    Zelicapavir (RSV-IN-7) (example 253) is an orally active RSV inhibitor (EC50: < 0.4 μΜ).
    Zelicapavir
  • HY-120632
    BMS-433771
    		Inhibitor 99.96%
    BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease.
    BMS-433771
  • HY-P99586
    Suptavumab
    		Inhibitor
    Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
    Suptavumab
  • HY-12994
    VP-14637
    		Inhibitor ≥99.0%
    MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC50 of 1.42 ng/mL.
    VP-14637
  • HY-123475A
    Sisunatovir hydrochloride
    		Inhibitor 98.61%
    Sisunatovir (RV521) hydrochloride is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice.
    Sisunatovir hydrochloride
  • HY-11098
    JNJ 2408068
    		Inhibitor
    JNJ 2408068 is a potent RSV (respiratory syncytial virus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg.
    JNJ 2408068
  • HY-W013605A
    4-Methoxycinnamaldehyde
    		Inhibitor 99.30%
    4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratory syncytial virus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL.
    4-Methoxycinnamaldehyde
  • HY-109004
    Enzaplatovir
    		Inhibitor 99.98%
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection.
    Enzaplatovir
  • HY-115574
    RSV L-protein-IN-1
    		Inhibitor 98.09%
    RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection.
    RSV L-protein-IN-1
  • HY-158824A
    Asvasiran sodium
    Asvasiran sodium is a siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication.
    Asvasiran sodium
  • HY-126303
    GS-443902
    		Inhibitor 99.87%
    GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir.
    GS-443902
  • HY-109004A
    (S)-Enzaplatovir
    		Inhibitor 99.73%
    (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77).
    (S)-Enzaplatovir
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity